BridgeBio Pharma, Inc BridgeBio (NASDAQ: BBIO) Ink Asset Purchase Agreement with Sentynl Therapeutics BridgeBio Pharma, Inc. (NASDAQ: BBIO) and Sentynl Therapeutics, Inc. (Sentynl) confirmed the finalization of an asset purchase agreement for the sale of BridgeBio’s NULIBRY (Fosdenopterin) for Injection. Sentynl’s
